US CDC adds seal of approval to Pfizer-BioNTech vaccine

31 August 2021

The US Centers for Disease Control and Prevention (CDC) has officially endorsed the recommendation for use of tozinameran, the coronavirus vaccine produced by Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX).

Formerly available under an Emergency Use Authorization (EUA), the vaccine recently received full approval in the USA from the US Food and Drug Administration.

The vaccine has been offered in Europe under the Comirnaty moniker, a brand name which will now also be used in the USA, as Pfizer ramps up efforts to market the product for subsequent rounds of booster shots.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK